AUTHORS
Mohamad Mohty, MD, PhD, David Michonneau, MD, PhD2, Michael Loschi, MD, PhD3, Florent Malard, MD, PhD4, Emilie Lanoy, MD5, Patrice Ceballos, MD6, Leonardo Magro7, Raynier Devillier, PhD8, Martin Carre, MD9, Marion Klemencie10, Patrice Chevallier, MD, PhD11, Cristina Castilla-Llorente, MD12, Laetitia Souchet13, Sylvain Chantepie, MD14, Anne Huynh, MD15, Alban Villate, MD16, Hélène Labussière-Wallet, MD17, Edouard Forcade, MD, PhD18, Pascal Turlure19, Natacha Maillard20, Jerome Cornillon, MD21, Nicolas Rodrigues22, Magalie Joris, MD23, Darko Kiprijanovski24, Anne-Lise Vataire25, Noémie Allali26, Sandrine Dos Santos27
AFFILIATIONS
1 Sorbonne Université, Paris, France
2 Hôpital Saint-Louis, Paris, France, INSERM, Paris, France
3 Centre Hospitalier Universitaire de Nice, Nice, France
4 Hôpital Saint-Antoine, Paris, France
5 AP-HP, Hôpital Européen Georges Pompidou (Unité de Recherche Clinique), INSERM (Centre d'Investigation Clinique 1418), Paris, France
6 Centre Hospitalier Universitaire de Montpellier / Saint-Eloi, Montpellier, France
7 Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
8 Institut Paoli-Calmettes, Marseille, France
9 Centre Hospitalier Universitaire de Grenoble Alpes, La Tronche, France
10 Centre Hospitalier d’Angers, Angers, France
11 Centre Hospitalier Universitaire de Nantes, Nantes, France
12 Gustave Roussy Paris Cancer Campus, Villejuif, France
13 Hôpital Pitié-Salpêtrière, Paris, France
14 Centre Hospitalier Universitaire de Caen, Caen, France
15 CHU/Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France
16 Centre Hospitalier Universitaire de Tours, Tours, France
17 Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite, France
18 Hôpital Haut Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France
19 Hôpital de Limoges, Hôpital Dupuytren, Limoges, France
20 Centre Hospitalier Universitaire de Poitiers, Poitiers, France
21 Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France
22 CHU Rouen Normandie Hôpital Charles-Nicolle, Rouen, France
23 Centre Hospitalier Universitaire d’Amiens-Picardie, Amiens, France
24 Sanofi Winthrop Industrie, Gentilly, France
25 Sanofi Winthrop Industrie, Gentilly, France
26 Sanofi Winthrop Industrie, Gentilly, France
27 Sanofi Winthrop Industrie, Gentilly, France
ABSTRACT
Introduction: Belumosudil (BEL), a Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, became available in France for the treatment of chronic graft-versus-host disease (cGVHD) through the compassionate use program (CUP) in March 2022. Given the limited availability of comparative evidence on the evaluation of BEL efficacy, we assessed effectiveness among patients who initiated BEL through the French CUP compared with those who initiated other systemic treatments for cGVHD.
Methods: The STARMANIA study is a French, non-interventional, multicenter, retrospective cohort of patients aged 12 years or older, with cGVHD, who initiated BEL (May 2, 2022, July 31, 2024), and/or who initiated at least one best available therapy (BAT) (May 1, 2015, May 1, 2022). Eligible patients had received 2 to 5 lines of treatment (LOT) for cGVHD, including corticosteroids (CS) and ruxolitinib (RUX). Two populations were analyzed: a Real-life (RL) population, including all patients, irrespective of the number of prior LOT and the date of initiation, and a Trial-like (TL) population, restricted to patients meeting strict protocol eligibility criteria. The LOT were classified either as BEL (obtained from patients treated with BEL) or BAT (obtained from patients both treated and not treated with BEL) and served as the primary statistical analysis. Endpoints included overall response rate (ORR) at 6 months, best ORR at any time, and organ-specific ORR at 6 months (RL population only), and were assessed using propensity score matching and inverse probability treatment weighting methods adjusted for within-patient correlation associated with repeated LOT in the same patient. Due to the retrospective design, only adverse events (AEs) leading to interruption/discontinuation and/or death were collected and analyzed in the overall RL population regardless of patient or LOT groups (BEL or BAT).
Results: The 159 patient-RL population comprised 104 BEL-treated patients and 55 BAT-treated patients contributing to 104 BEL LOT and 204 BAT LOT. The 127 patient-TL population included 81 BEL-treated patients and 43 BAT-treated patients contributing to 81 BEL LOT and 112 BAT LOT. Median follow-up was 50.7 months (BEL-treated) and 64.3 months (BAT-treated) in the RL population (48.6 and 71.0 months, respectively in the TL population). Median age at transplant was 54.4 (BEL-treated) and 55.2 years (BAT-treated) in the RL population (55.0 and 56.9 in the TL population). Acute myeloid leukemia was the primary transplant indication (32.7% BEL-treated and 30.9% BAT-treated) in the RL population (32.1% BEL-treated and 32.6% BAT-treated in the TL population). Severe cGVHD at initial diagnosis was present in 46.2% (BEL-treated) and 34.5% (BAT-treated) in the RL population (45.7% and 39.5% respectively, in the TL population). Patients received a median of 4 systemic therapies post CS and RUX, except patients treated with BAT only in the TL population who received a median of 5 systemic treatments. In the RL population, ORR at 6 months was significantly higher with BEL versus BAT (35.9% vs. 26.1%; p=0.020) as was best ORR (55.2% vs. 43.8%; p=0.007). Results were similar in the TL population (ORR at 6 months: 39.0% vs. 21.9%; p=0.001; best ORR: 59.2% vs. 40.8%; p<0.001). Among the 308 eligible LOT in the RL population, organ-specific ORR at 6 months favored BEL in skin (45.8% vs. 25.0%), eyes (32.2% vs. 18.7%) and mouth (29.0% vs. 25.0%), while lung response was comparable (28.6% in BEL vs. 25.1% in BAT). In the RL population, 55/159 patients (34.6%) experienced ≥ 1 AE leading to temporary interruption and/or permanent interruption and/or death.
Conclusion: The study provides the first comparative effectiveness evidence of BEL vs. BAT in the treatment of cGVHD for French patients who previously received at least 2 LOT. Although safety data were limited, these findings support the added therapeutic value of BEL in patients with treatment refractory cGvHD.
DISCLOSURES
Mohamad Mohty, MD, PhD: Therakos - Consultancy (Includes expert testimony); Astellas Pharma - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda Oncology - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Stremline Therapeutics Inc. - Consultancy (Includes expert testimony); Janssen Cilag EMEA - Consultancy (Includes expert testimony); OncoPep. Inc. - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Medac Pharma - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)